FeetMe

FeetMe develops innovative digital insoles for healthcare and sports, providing advanced analysis of gait and ground forces. Their technology enhances patient care and athletic performance through real-time data collection and feedback. FeetMe, founded in 2013 in Paris, France, focuses on creating digital insoles equipped with pressure sensors to analyze gait and foot health. The company has successfully completed 6 deals, with the most recent funding round being a Series A in October 2019, raising EUR 2.

44 million led by LBO France, bringing the total amount raised to EUR 2. 44 million and the post-money valuation to EUR 17. 81 million. FeetMe specializes in advanced digital insoles designed for both walking and running, aimed primarily at healthcare professionals, athletes, and patients with specific foot-related health concerns.

Their core product, FeetMe One, integrates eighty pressure sensors capable of measuring plantar pressure with a temporal resolution of 100 Hz, delivering detailed real-time analytics on gait and ground contact forces. These smart insoles connect via Bluetooth to smartphones, facilitating seamless data collection and analysis in various settings, including clinical environments and ecological contexts. The technology is particularly beneficial for post-surgery assessments, orthotic design, and managing diabetic foot complications by providing immediate feedback to users and healthcare providers. FeetMe products are sold primarily in European markets, with focus areas including France, Germany, and the United Kingdom, while also exploring opportunities in other regions where diabetes and gait-related issues are prevalent.

FeetMe generates revenue primarily through B2B transactions with healthcare professionals who integrate their insoles into patient care regimens and clinical practices. The sales model is structured around direct transactions with clinics and hospitals, whereby healthcare providers purchase FeetMe products for use in biomechanical assessments and patient monitoring. The company reported revenue of EUR 678,276 for the most recent year, 2021. The company’s key offerings, including FeetMe One and FeetMe MySoles, are designed to enhance patient outcomes and are marketed as essential tools for modern podiatric assessments.

By focusing on clinical applications and expanding into sports performance metrics, FeetMe aims to establish a robust revenue stream from diverse user bases, including athletes and individuals focused on preventive care. FeetMe's strategy for future growth includes the introduction of new products aimed at enhancing user experience and expanding functionality. The company plans to penetrate additional markets, particularly targeting regions with high prevalence of diabetic foot issues and sports performance needs. With the recent Series A funding of EUR 2.

44 million, which values FeetMe at EUR 17. 81 million post-money, the company aims to allocate resources towards product development and market expansion initiatives to bolster its position in the healthcare and sports sectors.